Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

Study Identifier:
ALXN1920-HV-101
ClinicalTrials.gov Identifier:
NCT05751642
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: ALXN1920
  • Biological: Placebo
Date
Apr 2023 - Dec 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: ALXN1920
  • Biological: Placebo
Date
Apr 2023 - Dec 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1920 subcutaneous (SC) and of a single dose of ALXN1920 intravenous (IV) in healthy adult participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
Grafton, Auckland, New Zealand, 1010
Status
N/A
Location
Research Site
Christchurch, New Zealand, 8011
Status
N/A